Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

World journal of gastroenterology - 7 Feb 2015

Bae Jeong Mo, Lee Tae Hun, Cho Nam-Yun, Kim Tae-You, Kang Gyeong Hoon

Abstract excerpt

AIM: To investigate the clinicopathologic characteristics and prognostic implications associated with loss of CDX2 expression in colorectal cancers (CRCs). METHODS: We immunohistochemically evaluated CDX2 expression in 713 CRCs and paired our findings to clinicopathologic and molecular characteristics of each individual. Endpoints included cytokeratin 7 and CK20 expression, microsatellite instability, CpG island...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CDX2 Transcription Factor
Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Down-Regulation

Share to Kaplan-Meier Estimate

Share to Multivariate Analysis

Share to Neoplasm Staging

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 25663765
DOI: 10.3748/wjg.v21.i5.1457
PMCID: PMC4316088

Genes

CDX2
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.PMID 25663765Read ↗

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal CancerSemantic proximity Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.Semantic proximity Read ↗

CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal CarcinomaSemantic proximity Read ↗

Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal CancerSemantic proximity Read ↗

The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.Semantic proximity Read ↗

Altered expression of CDX2 in colorectal cancersSemantic proximity Read ↗

Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.Semantic proximity Read ↗

Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.Semantic proximity Read ↗

CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwaySemantic proximity Read ↗

Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSemantic proximity Read ↗

Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohortsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.